Markus Joerger, M.D., Ph.D. will present new data from a multi-center Phase 1b/2a clinical trial of IP-001 at the American Society of Clinical Oncology (ASCO) Annual Meeting during a poster session on May 30, 2026.

The results add to growing momentum in immuno-oncology and further support Immunophotonics’ strategy of converting local tumor treatment into systemic cancer control through innovative therapeutic approaches.

This work reflects the combined efforts of clinical investigators, research partners, and the patients who make this progress possible through participation in clinical trials. While encouraged by these findings, the company remains focused on advancing its pipeline and delivering meaningful therapeutic options for patients with cancer.

🔗 Read the full press release here.